MEGHAN EGNER: Open Payments
NPI 1053067009 · HARRISBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,120 in 220 payments from 18 companies in 2025. Trend: 2023 $473 · 2024 $1,733 · 2025 $4,120
Food & beverage: $4,021Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 58 | $1,063 |
| ABBVIE INC. | 41 | $772 |
| Madrigal Pharmaceuticals | 13 | $502 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 27 | $339 |
| Regeneron Healthcare Solutions, Inc. | 14 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $205 |
| Celltrion USA Inc. | 12 | $188 |
| Ardelyx, Inc. | 9 | $159 |
| Johnson & Johnson Health Care Systems Inc. | 1 | $133 |
| Ipsen Biopharmaceuticals, Inc | 8 | $126 |
Products named: TREMFYA, REZDIFFRA, XIFAXAN, DUPIXENT, RINVOQ, LINZESS, VEGZELMA, IBSRELA.
Industry payments across PA — which companies pay providers there.
